| 000 | 00978 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518070404.0 | ||
| 264 | 0 | _c20200121 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a0171-2004 | ||
| 024 | 7 |
_a10.1007/164_2019_302 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKruizinga, Matthijs D | |
| 245 | 0 | 0 |
_aThe Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints. _h[electronic resource] |
| 260 |
_bHandbook of experimental pharmacology _c2019 |
||
| 300 |
_a371-397 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstandards |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aResearch Design _xtrends |
| 700 | 1 | _aStuurman, Frederik E | |
| 700 | 1 | _aGroeneveld, Geert J | |
| 700 | 1 | _aCohen, Adam F | |
| 773 | 0 |
_tHandbook of experimental pharmacology _gvol. 260 _gp. 371-397 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/164_2019_302 _zAvailable from publisher's website |
| 999 |
_c30293694 _d30293694 |
||